BNTX Stock: Price, Earnings History and SEC Filings
BioNTech SE (BNTX) last traded at $88.17, down 1.08% on the latest session and down 10.3% over the past month. In its most recent reported quarter (Jun 2026) earnings per share were $-3.03 against an analyst estimate of $-2.58, a miss of 17.4%.
$88.17 -1.08%
1 month-10.31%
52-week high$124.00
52-week low$79.52
Volume631,915
ExchangeNasdaqGS
Price data from Yahoo Finance, as of Oct 30, 2026. May be delayed.
BNTX earnings history
| Quarter | Reported | EPS | Estimate | Surprise |
|---|---|---|---|---|
| Jun 2026 | Aug 4, 2026 | $-3.03 | $-2.58 | -17.44% |
| Mar 2026 | May 5, 2026 | $-2.28 | $-2.52 | +9.52% |
| Dec 2025 | Mar 10, 2026 | $-0.38 | $-0.22 | -72.73% |
| Sep 2025 | Nov 3, 2025 | $-0.14 | $0.75 | -118.67% |
BNTX beat the analyst EPS estimate in 1 of its last 4 reported quarters. Source: Nasdaq.
Latest SEC filings for BNTX
SEC filing data is not available right now. You can search for BNTX on SEC EDGAR.
BNTX news
- BioNTech SEOct 30, 2026 · 247wallst.com
- BMY Q3 Earnings Tops Estimates, Higher Charges Weigh on OutlookOct 29, 2026 · finance.yahoo.com
- BioNTech (BNTX) Phase 3 Breast Cancer Win Comes With A Lung Safety WarningOct 28, 2026 · finance.yahoo.com
- Moderna Jumps 4% Despite William Blair Downgrade on Valuation; Novavax and BioNTech Edge HigherOct 28, 2026 · 247wallst.com
- Pfizer Stock Ahead of Q3 Earnings: To Buy or Not to Buy?Oct 28, 2026 · finance.yahoo.com
- The $1.5 Billion Question Facing Tempus AI Ahead of Nov. 2 EarningsOct 27, 2026 · 247wallst.com
- Moderna Tumbles 7% as Cancer Vaccine Selloff Deepens; BioNTech Falls 3%, Pfizer Holds SteadyOct 26, 2026 · 247wallst.com
- BioNTech and DualityBio Announce Topline Results of the DYNASTY-Breast02 Global Phase 3 Clinical Trial Evaluating Trastuzumab Pamirtecan in HR+/HER2-low Metastatic Breast CancerOct 26, 2026 · finance.yahoo.com
About BioNTech SE
BioNTech SE (BNTX) is a US-listed public company on Nasdaq.